Companies /Healthcare

Alkermes plc

NASDAQ: ALKS Drug Manufacturers - Specialty & Generic
$39.08
▼ $0.65 (−1.64%) today
Markets closed · 1:19am ET

24/7 Wall St. View

Price Prediction Our analysts’ 12-month view: target, optimistic case, and floor. ALKS price prediction → Earnings Miss −100.0% EPS vs. the estimate, revenue, and how the market reacted. ALKS earnings history →

ALKS at a Glance

Valuation
Market cap
$6.7B
P/E ratio
104.6
Profitability
Revenue (TTM)
$1.7B
Profit margin
4.0%
EPS (TTM)
$0.38
Price
52-week range
$27 – $56
Street target
$56.28
Earnings
Next report
Oct 27, 2026
Q2 2026 EPS
$0.00
vs. $0.29 est.
−100.0%

Headquartered in Connaught House, Dublin Fiscal year ends December NASDAQ: ALKS alkermes.com

About Alkermes

Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. The company's proprietary commercial portfolio includes treatments for alcohol dependence (VIVITROL), opioid dependence (VIVITROL), schizophrenia (ARISTADA, LYBALVI), bipolar I disorder (LYBALVI), and narcolepsy (LUMRYZ, acquired through the February 2026 acquisition of Avadel Pharmaceuticals). Alkermes also generates manufacturing and royalty revenues from partnered long-acting injectable antipsychotic products marketed by Johnson & Johnson (XEPLION, INVEGA TRINZA/TREVICTA, INVEGA HAFYERA/BYANNLI, RISPERDAL CONSTA) and from VUMERITY, a multiple sclerosis treatment marketed by Biogen. The company's pipeline features orexin 2 receptor agonists in development for neurological disorders including ADHD, fatigue associated with multiple sclerosis and Parkinson's disease, as well as late-stage clinical candidates for narcolepsy and idiopathic hypersomnia. Alkermes has a research and development center in Massachusetts and a manufacturing facility in Ohio. Updated

Revenue by Segment · Q2 2026
  1. VIVITROL25%
  2. ARISTADA19%
  3. LUMRYZ19%
  4. LYBALVI19%
  5. Partnered Long-Acting Antipsychotics10%
  6. VUMERITY6%

Latest Activity

House trade disclosureGilbert Ray Cisneros, Jr.U.S. Representative (House), California
  • ABTAbbott Laboratories Common Stock (ABT)Buy$1K – $15KSep 18
  • AEIS150 Main Street Trust > Bank of America Advanced Energy Industries, Inc. - CommoBuy$1K – $15KSep 29
  • ALKS150 Main Street Trust > Bank of America Alkermes plc - Ordinary Shares (ALKS)Buy$1K – $15KSep 29
  • ALGM150 Main Street Trust > Bank of America Allegro MicroSystems, Inc. - Common StocBuy$1K – $15KSep 29
  • APP150 Main Street Trust > Bank of America Applovin Corporation - Class A Common StBuy$1K – $15KSep 18
  • ATRC150 Main Street Trust > Bank of America AtriCure, Inc. - Common Stock (ATRC)Partial sell$1K – $15KSep 29
  • BCPCBalchem Corporation - Common Stock (BCPC)Buy$1K – $15KSep 17
  • BHE150 Main Street Trust > Bank of America Benchmark Electronics, Inc. Common StockBuy$15K – $50KOct 1
+ 49 more trades in this filing
Made public 39 days after the earliest trade

A former Pentagon undersecretary just disclosed 57 trades in one filing, with the heaviest buying in semiconductors and electronics manufacturing: NXP, ON Semiconductor and Benchmark Electronics all picked up in size. The disclosure landed 39 days after the earliest trade.

Read more

ALKS Coverage

8:50am ET
Investing

Wednesday’s Top Analyst Upgrades and Downgrades: Applied Materials, CrowdStrike, First Solar, Newmont, Occidental Petroleum, Palo Alto Networks, Take-Two Interactive, Twilio, Zscaler and More

Wednesday's top analyst upgrades and downgrades included Ally Financial, Applied Materials, CrowdStrike, Fidelity National Information Services, First Solar, Fortinet, Newmont, Occidental Petroleum, Palo Alto Networks, Take-Two Interactive Software, Trade Desk, Twilio and…

ALKS ALLY AMAT
Lee Jackson
Load More

Frequently Asked Questions

What does Alkermes do?

Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience.

What is the ALKS stock price target?

The Wall Street consensus 12-month price target for ALKS is $56.28. ALKS price prediction →